The FDA last week...

...rejected AstraZeneca’s application to expand its IL-5 inhibitor Fasenra into chronic rhinosinusitis with nasal polyps. The injectable is currently approved to treat asthma, where it holds covered or better status for 78% of all insured lives under the pharmacy benefit. 32.9% of covered lives have preferred access to Fasenra, largely with utilization management restrictions.

SOURCE: MMIT Analytics, as of 3/21/22